Metastatic breast cancer treated with lapatinib with a prolonged benefit

A case report and a review of therapeutic options available

Giulia Valeria Bianchi, Matteo Duca, Lorenzo Sica, Gabriella Mariani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A 53-year-old woman was treated, after trastuzumab progression of HER2-positive metastatic disease, with capecitabine plus lapatinib and subsequently with lapatinib alone. To date, she has had persistent remission of disease since 2009. Copyright - Il Pensiero Scientifico Editore.

Original languageEnglish
JournalTumori
Volume99
Issue number6
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Breast Neoplasms
Therapeutics
lapatinib
Trastuzumab
Capecitabine

Keywords

  • Lapatinib
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{60c077f77a9e4b7f82551132baed37bc,
title = "Metastatic breast cancer treated with lapatinib with a prolonged benefit: A case report and a review of therapeutic options available",
abstract = "A 53-year-old woman was treated, after trastuzumab progression of HER2-positive metastatic disease, with capecitabine plus lapatinib and subsequently with lapatinib alone. To date, she has had persistent remission of disease since 2009. Copyright - Il Pensiero Scientifico Editore.",
keywords = "Lapatinib, Metastatic breast cancer",
author = "Bianchi, {Giulia Valeria} and Matteo Duca and Lorenzo Sica and Gabriella Mariani",
year = "2013",
month = "11",
doi = "10.1700/1390.15466",
language = "English",
volume = "99",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Metastatic breast cancer treated with lapatinib with a prolonged benefit

T2 - A case report and a review of therapeutic options available

AU - Bianchi, Giulia Valeria

AU - Duca, Matteo

AU - Sica, Lorenzo

AU - Mariani, Gabriella

PY - 2013/11

Y1 - 2013/11

N2 - A 53-year-old woman was treated, after trastuzumab progression of HER2-positive metastatic disease, with capecitabine plus lapatinib and subsequently with lapatinib alone. To date, she has had persistent remission of disease since 2009. Copyright - Il Pensiero Scientifico Editore.

AB - A 53-year-old woman was treated, after trastuzumab progression of HER2-positive metastatic disease, with capecitabine plus lapatinib and subsequently with lapatinib alone. To date, she has had persistent remission of disease since 2009. Copyright - Il Pensiero Scientifico Editore.

KW - Lapatinib

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84894229267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894229267&partnerID=8YFLogxK

U2 - 10.1700/1390.15466

DO - 10.1700/1390.15466

M3 - Article

VL - 99

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -